Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2.
Journal
The Lancet. Child & adolescent health
ISSN: 2352-4650
Titre abrégé: Lancet Child Adolesc Health
Pays: England
ID NLM: 101712925
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
02
06
2021
revised:
28
06
2021
accepted:
29
06
2021
pubmed:
7
8
2021
medline:
24
9
2021
entrez:
6
8
2021
Statut:
ppublish
Résumé
In children, SARS-CoV-2 infection is usually asymptomatic or causes a mild illness of short duration. Persistent illness has been reported; however, its prevalence and characteristics are unclear. We aimed to determine illness duration and characteristics in symptomatic UK school-aged children tested for SARS-CoV-2 using data from the COVID Symptom Study, one of the largest UK citizen participatory epidemiological studies to date. In this prospective cohort study, data from UK school-aged children (age 5-17 years) were reported by an adult proxy. Participants were voluntary, and used a mobile application (app) launched jointly by Zoe Limited and King's College London. Illness duration and symptom prevalence, duration, and burden were analysed for children testing positive for SARS-CoV-2 for whom illness duration could be determined, and were assessed overall and for younger (age 5-11 years) and older (age 12-17 years) groups. Children with longer than 1 week between symptomatic reports on the app were excluded from analysis. Data from symptomatic children testing negative for SARS-CoV-2, matched 1:1 for age, gender, and week of testing, were also assessed. 258 790 children aged 5-17 years were reported by an adult proxy between March 24, 2020, and Feb 22, 2021, of whom 75 529 had valid test results for SARS-CoV-2. 1734 children (588 younger and 1146 older children) had a positive SARS-CoV-2 test result and calculable illness duration within the study timeframe (illness onset between Sept 1, 2020, and Jan 24, 2021). The most common symptoms were headache (1079 [62·2%] of 1734 children), and fatigue (954 [55·0%] of 1734 children). Median illness duration was 6 days (IQR 3-11) versus 3 days (2-7) in children testing negative, and was positively associated with age (Spearman's rank-order r Although COVID-19 in children is usually of short duration with low symptom burden, some children with COVID-19 experience prolonged illness duration. Reassuringly, symptom burden in these children did not increase with time, and most recovered by day 56. Some children who tested negative for SARS-CoV-2 also had persistent and burdensome illness. A holistic approach for all children with persistent illness during the pandemic is appropriate. Zoe Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging and Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation, and Alzheimer's Society.
Sections du résumé
BACKGROUND
In children, SARS-CoV-2 infection is usually asymptomatic or causes a mild illness of short duration. Persistent illness has been reported; however, its prevalence and characteristics are unclear. We aimed to determine illness duration and characteristics in symptomatic UK school-aged children tested for SARS-CoV-2 using data from the COVID Symptom Study, one of the largest UK citizen participatory epidemiological studies to date.
METHODS
In this prospective cohort study, data from UK school-aged children (age 5-17 years) were reported by an adult proxy. Participants were voluntary, and used a mobile application (app) launched jointly by Zoe Limited and King's College London. Illness duration and symptom prevalence, duration, and burden were analysed for children testing positive for SARS-CoV-2 for whom illness duration could be determined, and were assessed overall and for younger (age 5-11 years) and older (age 12-17 years) groups. Children with longer than 1 week between symptomatic reports on the app were excluded from analysis. Data from symptomatic children testing negative for SARS-CoV-2, matched 1:1 for age, gender, and week of testing, were also assessed.
FINDINGS
258 790 children aged 5-17 years were reported by an adult proxy between March 24, 2020, and Feb 22, 2021, of whom 75 529 had valid test results for SARS-CoV-2. 1734 children (588 younger and 1146 older children) had a positive SARS-CoV-2 test result and calculable illness duration within the study timeframe (illness onset between Sept 1, 2020, and Jan 24, 2021). The most common symptoms were headache (1079 [62·2%] of 1734 children), and fatigue (954 [55·0%] of 1734 children). Median illness duration was 6 days (IQR 3-11) versus 3 days (2-7) in children testing negative, and was positively associated with age (Spearman's rank-order r
INTERPRETATION
Although COVID-19 in children is usually of short duration with low symptom burden, some children with COVID-19 experience prolonged illness duration. Reassuringly, symptom burden in these children did not increase with time, and most recovered by day 56. Some children who tested negative for SARS-CoV-2 also had persistent and burdensome illness. A holistic approach for all children with persistent illness during the pandemic is appropriate.
FUNDING
Zoe Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging and Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation, and Alzheimer's Society.
Identifiants
pubmed: 34358472
pii: S2352-4642(21)00198-X
doi: 10.1016/S2352-4642(21)00198-X
pmc: PMC8443448
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
708-718Subventions
Organisme : Medical Research Council
ID : MC_PC_20058
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests CH, SS, KR, and JCP are employees of Zoe Limited. TDS reports being a consultant for Zoe Limited, during the conduct of the study. All other authors declare no competing interests.
Références
Lancet Child Adolesc Health. 2021 May;5(5):e12-e13
pubmed: 33713603
J Child Psychol Psychiatry. 2007 Aug;48(8):785-92
pubmed: 17683450
Int J Pediatr Otorhinolaryngol. 2021 Mar;142:110626
pubmed: 33477014
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1074-1080
pubmed: 32790663
Dev Med Child Neurol. 2010 Dec;52(12):1088-97
pubmed: 20875042
N Engl J Med. 2021 Feb 18;384(7):669-671
pubmed: 33406327
Lancet Child Adolesc Health. 2021 Jun;5(6):e22-e23
pubmed: 33891880
PLoS One. 2020 Nov 9;15(11):e0240784
pubmed: 33166287
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
J Infect Dis. 2013 Jan 1;207(1):80-8
pubmed: 23100562
Acta Paediatr. 2021 Mar;110(3):914-921
pubmed: 33205450
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Pediatrics. 2021 Sep;148(3):
pubmed: 34049958
Science. 2020 Jun 19;368(6497):1362-1367
pubmed: 32371477
Lancet Public Health. 2021 Jan;6(1):e21-e29
pubmed: 33278917
Arch Dis Child. 2017 Jun;102(6):522-528
pubmed: 28104625
Front Pediatr. 2020 Nov 02;8:591132
pubmed: 33224909
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Cochrane Database Syst Rev. 2020 Jul 7;7:CD013665
pubmed: 32633856
Br J Psychiatry. 2004 Jun;184:477-81
pubmed: 15172940
BMC Infect Dis. 2020 Aug 31;20(1):640
pubmed: 32867706
BMJ. 1994 Sep 24;309(6957):765-9
pubmed: 7950559
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
BMJ Open. 2011 Dec 12;1(2):e000252
pubmed: 22155938
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937